REG - C4X Discovery - C4X Discovery Holdings plc: Board Change

C4X Discovery HoldingsAnnouncement

20/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230620:nRST2222Da&default-theme=true

RNS Number : 2222D  C4X Discovery Holdings PLC  20 June 2023

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Board Change

 

 

20 June 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, today announces that Eva-Lotta Allan will step down as
Chair after five years of service with immediate effect. Clive Dix will
simultaneously become interim Executive Chair and a search will commence to
find a new Chief Executive Officer.  Clive Dix, who has held a variety of
leadership roles at C4XD over the past nine years, will be interim Executive
Chair until a new CEO is appointed in order to ensure a smooth transition,
after which point it is expected that he will assume a Non-Executive Board
role.

 

Eva-Lotta became Chair in July 2018 and steps down now to focus on her
portfolio of other Board director roles.  The search will now be initiated to
recruit a new CEO of C4XD, ideally with strong leadership skills, an
international network and IR experience in global public markets, and a track
record of building a company with products that have entered clinical
development.

 

Clive Dix, CEO of C4XD, said: "I would like to thank Eva-Lotta, both
personally and on behalf of the Board for her guidance and support over the
past five years as, together, we have built C4XD into a strong company with an
established reputation for drug discovery expertise.  The business is one I
feel extremely confident and passionate about and I look forward to working
with the Board to find a suitable CEO successor to continue to drive our new
strategy forward with the focus in immuno-inflammatory diseases."

 

Eva-Lotta Allan, Chair of C4XD, commented: "Over the past five years we have
built a commercially attractive pipeline and executed several value-creating
deals for C4XD programmes with leading pharma companies and, after five years,
I now feel it is the right time to hand the reigns to Clive as interim
Executive Chair.  A smooth succession plan will allow us to bring in a new
CEO with the right experience to take the Company to its next stage, thereby
ensuring that C4XD continues to deliver on its vision, strategy and, most
importantly new therapies to improve the lives of patients with
immuno-inflammatory diseases. I have enjoyed working with the CX4D team and
the Board and wish everyone at C4XD well."

 

- Ends -

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company, combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world‑leading medicines.  We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced candidate
molecule design and patient stratification capabilities, generating small
molecule drug candidates across multiple disease areas focused on
immuno-inflammation.  Our commercially attractive portfolio ranges from
early-stage target opportunities to late-stage Drug Discovery programmes and
we have three commercially partnered programmes with one candidate in clinical
development.

 

For more information visit us at www.c4xdiscovery.com
(http://www.c4xdiscovery.com) or follow us on twitter @C4XDiscovery.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFDFUUEDSEEM